Table 8.
aPharmacokinetics of compound 3 in mouse
| Route | Dose (mg/kg) |
%F | Cmax, po (ng/mL) |
Tmax, po (h) |
AUC0-last, po (ng•h/mL) |
CL, iv (mL/min/kg) |
Vd, iv (L/kg) |
t½, iv (h) |
|---|---|---|---|---|---|---|---|---|
| IV | 1.0 | -- | -- | -- | -- | 10.6 | 1.14 | 3.9 |
| PO | 0.83 | 47.3 | 178 | 0.05 | 750 | -- | -- | -- |
a
Oral bioavailability (%F), area under the concentration-time curve from time zero to the last measurable concentration (AUC0-last), clearance (CL), maximum observed plasma concentration (Cmax), intravenous (IV), per os (PO), elimination half-life (t½), time to Cmax (Tmax), volume of distribution (Vd)